Science Explorer Back to mapMap

Most cited papers from Vyne Therapeutics (United States)

What are the most cited papers from Vyne Therapeutics (United States)?

The most cited paper from Vyne Therapeutics (United States) is "In vivo editing of lung stem cells for durable gene correction in mice" (Yehui Sun et al., 2024), with 182 citations. Next come "Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial" (120) and "Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial" (115).

Showing 50 of 65 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 In vivo editing of lung stem cells for durable gene correction in mice Yehui Sun et al. · Science Open access 13 Jun 2024 182
2 Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial Gil Yosipovitch, Sonja Ständer, Matthew B. Kerby et al. · Journal of the American Academy of Dermatology Open access 17 Feb 2018 120
3 Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, Paul Kwon, Joe Hirman et al. · Journal of the American Academy of Dermatology Open access 17 Mar 2019 115
4 Diagnostic and treatment algorithm for chronic nodular prurigo Hartmut F. Ständer, Sarina B. Elmariah, Claudia Zeidler et al. · Journal of the American Academy of Dermatology 13 Jul 2019 100
5 Bronchial Rheoplasty for Treatment of Chronic Bronchitis. Twelve-Month Results from a Multicenter Clinical Trial Arschang Valipour, Sebastián Fernández-Bussy, Alvin Ing et al. · American Journal of Respiratory and Critical Care Medicine Open access 14 May 2020 78
6 Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial Albert Sean Chiou, Sara Choi, Melissa Barriga et al. · Journal of the American Academy of Dermatology Open access 18 Sep 2019 75
7 Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis Pavel Dřevı́nek, Tacjana Pressler, Marco Cipolli et al. · Journal of Cystic Fibrosis Open access 7 Jun 2019 63
8 Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need Manuel P. Pereira, Sameh A. Basta, Jolene N Moore et al. · Journal of the European Academy of Dermatology and Venereology Open access 5 Jun 2018 55
9 Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial David M. Pariser, Jerry Bagel, Mark Lebwohl et al. · Journal of the American Academy of Dermatology 30 Jan 2020 49
10 Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors Pamela N. Münster, Andrew E. Greenstein, Gini F. Fleming et al. · Clinical Cancer Research Open access 18 May 2022 38
11 Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis Miriam Kimel, Claudia Zeidler, Paul Kwon et al. · JAMA Dermatology Open access 16 Sep 2020 34
12 Prevalence of Prurigo Nodularis in Poland Anna Ryczek, Adam Reich · Acta Dermato Venereologica Open access 2020 30
13 The NK1 receptor antagonist serlopitant for treatment of chronic pruritus Sonja Ständer, Mary C. Spellman, Paul Kwon et al. · Expert Opinion on Investigational Drugs Open access 4 Jul 2019 27
14 Automated detection of progressive speech changes in early Alzheimer's disease Jessica Robin, Mengdan Xu, Aparna Balagopalan et al. · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring Open access Apr 2023 23
15 Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton’s Tyrosine Kinase Yong Du, Ling Lei, Huihua Ding et al. · Frontiers in Immunology Open access 8 Jul 2022 13
16 Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX103 1.5% Minocycline Topical Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea. Linda Stein Gold, JAMES Q. Del Rosso, Leon Kircik et al. · PubMed Open access Nov 2020 10
17 Examining crossover and postprotocol therapies in first‐line immunotherapy trials in non–small cell lung cancer Aakash P. Desai, Caleb Joshua Smith, Joshua C. Pritchett et al. · Cancer Open access 14 Feb 2024 7
18 Lipid nanoparticle-encapsulated Dnai1 mRNA rescues ciliary activity in primary ciliary dyskinesia mouse cell models Amanda J Smith, Patrick R. Sears, Mirko Hennig et al. · Journal of Cell Science Open access 18 Sep 2025 6
19 730. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ridinilazole Compared with Vancomycin for the Treatment of Clostridioides difficile Infection Pablo C. Okhuysen, Mayur S. Ramesh, Kevin W. Garey et al. · Open Forum Infectious Diseases Open access Dec 2022 6
20 Using Color to Understand Light Transmission G. Grigoryan, Ivan T. Lima, Yu Tian et al. · Optics and Photonics News Aug 2000 6
21 Safety and Efficacy of DYNE-101 in Adults with DM1: Phase 1/2 ACHIEVE Trial Data (S16.003) Daniel Wolf, Guillaume Bassez, Jordi Díaz‐Manera et al. · Neurology 7 Apr 2025 5
22 Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions. Terry M. Jones, Iain Stuart · PubMed Open access Mar 2021 5
23 Impact of a G-CSF Policy to Reduce Low-Value Care on Guideline Adherence and Mortality Chinelo Orji, Carolyn M. Brown, John Russell Hoverman et al. · JCO Oncology Practice Open access 14 Apr 2021 5
24 Selectivity of the Time-Dependent M. tuberculosis LeuRS Inhibitor Ganfeborole Is Driven by Target Vulnerability Mingqian Wang, YongLe He, Siobhan A. Cohen et al. · ACS Chemical Biology Open access 3 Dec 2025 4
25 279th ENMC international workshop: Classification, clinical care, outcome measures and biomarkers in childhood onset facioscapulohumeral dystrophy: towards standardizing clinical care and ensuring clinical trial readiness. Hoofddorp, The Netherlands, 1-3 November 2024 Jildou N. Dijkstra et al. · Neuromuscular Disorders Oct 2025 4
26 A Prospective, Multicenter, Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate the Safety and Efficacy of a Combination Of 3% Minocycline and 0.3% Adapalene Topical Foam Formulation for the Treatment of Moderate-to-Severe Acne JAMES Q. Del Rosso, Linda Stein Gold, Zoe Diane Draelos et al. · SKIN The Journal of Cutaneous Medicine Open access 27 Oct 2020 4
27 Probing protein surfaces for `hot spots': a new frontier Allen Krantz · Trends in biotechnology Dec 1998 4
28 2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A – Recommendations on Biomarkers Discovery, Development, Validation & Regulatory Approval, Ligand-Binding Assays Sarah Hersey et al. · Bioanalysis Open access 2 Dec 2025 3
29 Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer Arthi Sridhar, Howard West, Eric Kumar Singhi · Clinical Lung Cancer 30 Apr 2024 3
30 Teledermatology Melissa A. Nickles, Andrea M. Rustad, Peter Lio · Journal of the Dermatology Nurses’ Association 24 Feb 2022 3
31 Apremilast and Systemic Retinoid Combination Treatment for Moderate to Severe Palmoplantar Psoriasis Tali Czarnowicki, B. Peter Rosendorff, Mark Lebwohl · Cutis Open access Jul 2020 3
32 A76-28 Safety and Bronchoscopy Evaluation of an Inhaled mRNA Treatment for Primary Ciliary Dyskinesia Due to Disease Causing DNA Variants in the DNAI1 Gene: Phase 1a Single-dose and Phase 1b Multiple-dose Open-label Trials M R Loebinger, M Bottier, P L Shah et al. · American Journal of Respiratory and Critical Care Medicine Jun 2026 2
33 15P Intracranial (IC) efficacy of ivonescimab (ivo) plus chemotherapy (chemo) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutated non-small cell lung cancer (NSCLC) in the HARMONi study X. Le, A. Passaro, J. Laskin et al. · ESMO Open Open access 17 Mar 2026 2
34 Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer X. Le, S. Popat, J.V. Heymach et al. · ESMO Open Open access 27 Jan 2026 2
35 Squamous Non-Small Cell Lung Cancer: Current and Emerging Treatment Options Paul K. Paik, Jianjun Zhang, Howard West et al. · Clinical Lung Cancer Open access 7 Oct 2025 2
36 Pharmacokinetics and in vivo efficacy of epetraborole against Burkholderia pseudomallei Jason E. Cummings, Danara Flores, Vincent E. Guglielmi et al. · Scientific Reports Open access 22 Oct 2025 2
37 A Framework for Quantitative Systems Pharmacology Model Execution Victor V. Sokolov, Kirill V. Peskov, Gabriel Helmlinger · Handbook of experimental pharmacology Book chapter 2025 2
38 A Retrospective Review of Patients’ Response to Biologic Therapy for Psoriasis Jerry Bagel, Brianna Butler, Elise Nelson et al. · Journal of Drugs in Dermatology Open access Mar 2021 2
39 Integrated Safety and Efficacy Analysis of FMX103 1.5% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea: Results From Two Phase 3 Studies JAMES Q. Del Rosso, Linda Stein Gold, Leon Kircik et al. · SKIN The Journal of Cutaneous Medicine Open access 2 Sep 2020 2
40 Clinical and healthcare burden of myotonic dystrophy type 1 (DM1) in the United States: a claims-based study Johanna Hamel, Mihail Samnaliev, Lauren Do et al. · Journal of Medical Economics Open access 28 Feb 2026 1
41 Plain language summary: comparing ivonescimab with pembrolizumab in people with PD-L1–positive non-small cell lung cancer in the HARMONi–2 study L Wang, WenXiu Yao, H Shen et al. · Future Oncology Open access 28 Dec 2025 1
42 Loss of Age-Associated Increase in m6A-Modified RNA Contributes to GABAergic Dysregulation in Alzheimer's Disease Jenna L. Libera, Junming Hu, Tuyet-Anh Nguyen et al. · SSRN Electronic Journal PreprintOpen access 2025 1
43 133TiP: A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7 Antonio Passaro, Nicholas Girard, D. Rodriguez Abreu et al. · Journal of Thoracic Oncology Open access Mar 2025 1
44 Integrated Efficacy of FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Analyses of Efficacy in Clinically Relevant Subgroups of Patients JAMES Q. Del Rosso, Linda Stein Gold, Leon Kircik et al. · SKIN The Journal of Cutaneous Medicine Open access 27 Oct 2020 1
45 High unmet need in severe chronic pruritus in the United States: results from a survey of practicing community dermatologists Stuart Sedlack, Gil Yosipovitch, Matthew B. Kerby et al. · Itch Open access 29 Nov 2018 1
46 438 Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in epidermolysis bullosa patients Albert Sean Chiou, Sara Choi, Melissa Barriga et al. · Journal of Investigative Dermatology Open access 19 Apr 2018 1
47 POSTER: MPN-1076: Hematologic and Safety Profile of Epetraborole in a Non-Polycythemia Vera Patient Population George H. Talbot, Stanton Gerson, Bibiana Castañeda-Ruiz et al. · Clinical Lymphoma Myeloma & Leukemia Aug 2026 0
48 POSTER: MPN-1041: Epetraborole Demonstrates an Exposure-Dependent Effect on Erythropoiesis in Healthy Subjects Sanjay Chanda, Alex Smith, George H. Talbot · Clinical Lymphoma Myeloma & Leukemia Aug 2026 0
49 POSTER: MPN-1082: Exposure-Response Analyses of Hemoglobin Changes During Epetraborole Administration to Nonhuman Primates Predict Human Exposure-Response Relationships Christopher M. Rubino, Jeffrey Hammel, Sanjay Chanda et al. · Clinical Lymphoma Myeloma & Leukemia Aug 2026 0
50 D96-09 Safety and Effect on Mucociliary Clearance of RCT1100, an Inhaled Lipid Nanoparticle DNAI1 MRNA, in Patients With Primary Ciliary Dyskinesia Due to Disease Causing DNA Variants in the DNAI1 Gene: An Open-label, Multiple-dose, Phase 1b Trial C M Nygaard et al. · American Journal of Respiratory and Critical Care Medicine Jun 2026 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.